Moderna’s updated mRNA-1273.815 COVID-19 vaccine shows promising results in reducing symptomatic cases, hospitalizations, and deaths in high-risk and older adults in Germany. The study finds the vaccine to be more cost-effective and clinically beneficial than both no vaccination and Pfizer’s XBB.1.5 BNT162b2 vaccine.
Novartis recruits new ex-US leader from AbbVie as Marie-France Tschudin steps down
Marie-France Tschudin, Novartis’ president, innovative medicines international and chief commercial officer, is stepping down after almost seven years with the company. Taking over her spot
September 7, 2023